| h-f10d82a7 | NLRP3/Mitophagy Coupling Modulation | 0.68 | 0.75 | NLRP3 | promoted | 2026-04-12 | SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 |
| h-909199b568 | TREM2 R47H variant synergizes with APOE4 to collapse microglial lipid clearance | 0.68 | 0.72 | TREM2, APOE | proposed | 2026-04-22 | SDA-2026-04-04-gap-apoe4-lipid-metabolism |
| h-c463d225 | R-Loop Resolution Enhancement Therapy | 0.68 | 0.65 | SETX | debated | 2026-04-02 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-637a53c9 | Chaperone-Mediated APOE4 Refolding Enhancement | 0.68 | 0.60 | HSPA1A, HSP90AA1, DNAJB1, FKBP5 | debated | 2026-04-02 | sda-2026-04-01-gap-010 |
| h-0dea0ed5 | Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus | 0.68 | 0.40 | AQP1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-f71a9791 | Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution | 0.68 | 0.30 | GPR37 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-81fc2e051f | Mitochondrial Quality Control Failure | 0.68 | 0.65 | PINK1, PARK2, MFN2, SIRT3 | proposed | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-metrep-e58337c5a06 | Dasatinib plus Quercetin Senolytic Clearance of p16Ink4a-High Neurons in Alzheim | 0.68 | 0.75 | CDKN2A,BCL2,BCL2L1,FOXO3A,AKT1,PIK3CA,HSP90AA1 | proposed | 2026-04-28 | |
| h-metrep-e5842c76ad1 | Metabolic Checkpoint Failure in NG2+ Oligodendrocyte Progenitor Cells Drives Whi | 0.68 | 0.75 | NG2,AMPK,PRKAA1,TSC2,MTOR,RPTOR,SIRT1,CDKN2A,MBP,PLP1,OLIG1, | proposed | 2026-04-28 | |
| h-metrep-033391a0240 | NMN Adenosine Transport Enhancement for Cortical Neuron Senescence Rescue in Alz | 0.68 | 0.75 | SLC12A8,SIRT1,SRT2104,NMN,SIRT3 | proposed | 2026-04-28 | |
| h-metrep-5d3e6f6af6c | DRP1 S616 Hyperphosphorylation and MFN2 Downregulation Create a Vicious Cycle Dr | 0.68 | 0.75 | DRP1,MFN1,MFN2,CDK5,PRKCD,PARK2,PTEN,PGC1A,OPA1 | proposed | 2026-04-28 | |
| h-SDA-2026-04-26-gap | Soluble LRP1 (sLRP1) Ectodomain Shedding as a Blood-Based Indicator of Impaired | 0.68 | 0.52 | LRP1 (LDL Receptor Related Protein 1) | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-d3547d39c6 | Microglial NOX2 establishes an inflammatory ROS propagation loop around vulnerab | 0.68 | 0.73 | CYBB; NCF1; NCF2; RELA; NLRP3 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181140-0af1a353-debate |
| h-c1855f6c5c | Neuronal AMPK Restoration (H1): Direct Reversibility Test | 0.68 | 0.22 | PRKAA1/PRKAA2 (AMPKα1/α2) | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-180918-962b1ada-debate |
| h-dd0fe43949 | A downstream LRRK2-Rab10-JIP4 lysosomal stress loop promotes alpha-synuclein rel | 0.68 | 0.68 | LRRK2,RAB10,JIP4,SNCA | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-9180363b7c |
| h-d28c25f278 | Bacterial Tyramine–Induced DOPAL Accumulation in Enteric Neurons | 0.68 | 0.60 | TyrDC (bacterial), ALDH1A1, MAOB, SLC6A3 (DAT) | proposed | 2026-04-22 | sda-2026-04-01-gap-20260401-225155 |
| h-339142d2f8 | LRP1-Mediated Transcytosis for CNS Antibody Delivery | 0.68 | 0.68 | LRP1 (LRP1 gene); clathrin-mediated endocytosis pathway | proposed | 2026-04-22 | SDA-2026-04-02-gap-bbb-antibody-transport |
| h-25cfa8f46c | Pharmacological EZH2 Inhibition Resets Polycomb-Mediated Repression of Synaptic | 0.68 | 0.78 | EZH2/H3K27me3 | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-060512 |
| h-6b9dec7170 | AQP4 Dysregulation Promotes Neuroinflammation Through Impaired CNS-Peripheral Im | 0.68 | 0.68 | AQP4; IL6R; CD46 (complement) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e |
| h-f909089218 | Glial Neuroinflammatory Amplification by TDP-43 Pathology | 0.68 | 0.70 | TARDBP | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a |
| h-298c2f03 | GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade | 0.68 | 0.68 | GPX4 | proposed | 2026-04-17 | SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed |
| h-2f43b42f | ... | 0.68 | 0.70 | ... | proposed | 2026-04-03 | SDA-2026-04-02-gap-aging-mouse-brain-20260402 |
| 897f3e4a-f96a-4a65-b | Arginine Methylation Loss on FUS RGG Domains Drives Irreversible Phase Transitio | 0.68 | 0.48 | FUS | open | 2026-04-28 | 52661eaf-79f8-4647-8f48-3389f5af4d59 |
| h-a1edc6af93 | Cortical Layer 5 Pyramidal Neuron GluN2B-Mediated Hyperactivity Drives Tau Secre | 0.68 | 0.70 | GRIN2B (L5 pyramidal neurons); downstream: ADAM10/ADAM17 | proposed | 2026-04-28 | SRB-2026-04-28-h-var-e2b5a7e7db |
| h-7ed7b242de | TFEB-mediated transcriptional upregulation of lysosomal genes as a therapeutic s | 0.68 | 0.72 | TFEB (TFEC) | proposed | 2026-04-22 | SDA-2026-04-04-gap-lysosomal-cathepsin-ad |
| h-16ee87a4 | Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donat | 0.68 | 0.60 | GJA1 | proposed | 2026-04-03 | SDA-2026-04-01-gap-20260401231108 |
| h-76d375b520 | Gamma entrainment enhances TREM2-mediated microglial clearance of Aβ plaques via | 0.68 | 0.68 | TREM2 (triggering receptor expressed on myeloid cells 2); SY | proposed | 2026-04-28 | SRB-2026-04-28-h-bdbd2120 |
| h-seaad-5b3cb8ea | Complement C1QA Spatial Gradient in Cortical Layers | 0.68 | 0.55 | C1QA | proposed | 2026-04-03 | analysis-SEAAD-20260402 |
| h-ea5794f9 | Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification Biomarker | 0.68 | 0.45 | SLC16A1 | proposed | 2026-04-17 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| h-b9acf0c9 | Cell-Type Specific TFEB Modulation | 0.68 | 0.70 | TFEB | promoted | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| h-3bfa414a | Astrocyte-Mediated Microglial Memory Erasure | 0.68 | 0.59 | GFAP, S100B | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-4118a57ecd | Gamma entrainment corrects AD-related clock gene dysregulation to normalize hipp | 0.68 | 0.60 | PER1/PER2 (circadian clock genes); ARNTL (BMAL1); CREBBP (CR | proposed | 2026-04-28 | SRB-2026-04-28-h-bdbd2120 |
| h-3fdee932 | Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes | 0.68 | 0.50 | MAPT | proposed | 2026-04-14 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-var-69c66a84b3 | Microglial TREM2-Mediated Tau Phagocytosis Impairment | 0.68 | 0.71 | MAPT | proposed | 2026-04-12 | SDA-2026-04-03-26abc5e5f9f2 |
| h-SDA-2026-04-26-gap | Matrix Metalloproteinase-9/TIMP-1 Ratio in CSF Identifies Preclinical Tight Junc | 0.68 | 0.34 | MMP9, TIMP1 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| 29a49684-e9d9-48f5-9 | X-Linked KDM6A Escapes X-Inactivation to Drive Female-Biased Microglial Neuropro | 0.67 | 0.38 | KDM6A | open | 2026-04-28 | dfb32151-9c40-452d-8063-0c57bae5c3d6 |
| h-724e3929 | White Matter Oligodendrocyte Protection via CXCL10 Inhibition | 0.67 | 0.70 | CXCL10 | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-seaad-7f15df4c | Excitatory Neuron Vulnerability via SLC17A7 Downregulation | 0.67 | 0.60 | SLC17A7 | proposed | 2026-04-03 | analysis-SEAAD-20260402 |
| h-250b34ab | RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo deliv | 0.67 | 0.40 | RAB27A | debated | 2026-04-02 | sda-2026-04-01-gap-v2-89432b95 |
| h-38292315 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | 0.67 | 0.40 | HK2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-691b42f1 |
| h-var-c46786d2ab | Astrocytic-Mediated Tau Clearance Dysfunction via TREM2 Signaling | 0.67 | 0.71 | TREM2 | proposed | 2026-04-12 | SDA-2026-04-03-26abc5e5f9f2 |
| h-baba5269 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | 0.67 | 0.50 | OCT4 | debated | 2026-04-02 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| h-110fecd1f6 | Seed match plus local RNA structure jointly determine lncRNA-0021 binding to mmu | 0.67 | 0.61 | lncRNA-0021 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-150509-76c40dac-debate |
| h-6c347bffd7 | TREM2 Agonism to Promote Neuroprotective Microglial Phenotype in Alzheimer's Dis | 0.67 | 0.78 | TREM2 | proposed | 2026-04-29 | SDA-2026-04-28-gap-test-20260425-224949 |
| h-96aac98502 | Adaptive Closed-Loop Gamma/Theta-Gamma Entrainment of Entorhinal-Hippocampal Cir | 0.67 | 0.72 | N/A (electrophysiologic network target) | proposed | 2026-04-28 | SRB-2026-04-28-h-var-b7e4505525 |
| h-9dc6fc2bb1 | APOE4-Targeted Microglial Reprogramming via Anti-APOE4 Antibodies | 0.67 | 0.80 | APOE | proposed | 2026-04-26 | test-hypothesis-fixtures-v1 |
| h-78b2af94ab | Leaky Gut LPS Translocation Activates Systemic TLR4/MyD88 Signaling, Driving CNS | 0.67 | 0.78 | TLR4, MyD88, IRAK4, CCL2, CCR2, ZO-1 (TJP1) | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260425-225305 |
| h-a962a518d3 | FABP5/7 Inhibition (H2): Lipid Relay Interruption | 0.67 | 0.65 | FABP5/FABP7 (fatty acid binding proteins) | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-180918-962b1ada-debate |
| h-32b63761ed | Fyn-anchored dendritic tau/NMDAR signaling persists after transient Aβ exposure | 0.67 | 0.71 | MAPT,FYN,DLG4,GRIN2B | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-98a600b3ed |
| h-85b51a8f58 | Microglial TREM2 state determines whether C1q-tagged substrates are cleared adap | 0.67 | 0.71 | TREM2,TYROBP,C1QA,C1QB,C1QC,C3 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-afba1a80bd |